{"prompt": "['4. Evaluation of the main tumor associated antigens (TAA) inducible immunogenic cell death', '(such as HSP70, HSP90, HMBG1, EpCAM)', 'The day after radiotherapy repeat the same determinations as baseline', 'At the beginning of cycle 2, repeat the tests at points_ 1, 2 and 3 of the baseline', 'At disease progression repeat the tests at points 1, 2 and 3 of the baseline', '11.3 Translational materials and methods', '11.3.1 Sample Collection, handling and shipment', '15 ml blood samples collected at baseline, the day after RT, at the beginning of cycle 2, at disease', 'progression.', \"Plasma samples will obtained by centrifugating one vacutainer at 1500 g for 10'. Aliquotes of 600\", 'l in 2 ml cryovials should be kept at - 80\u00b0C.', 'PBMCs will be obtained through Ficoll separation, following standard procedures, from the', 'remaining two vacutainers. Cells have to be frozen as vital by planer instrument or by slow freezing', '(2h at 4\u00b0C, 2h at -20\u00b0C, then -80\u00b0C in aliquotes of 3x10^6 cells.', 'All cryovials, both plasma and PBMCs, should be kept at -80\u00b0C until shipping by courier to the', 'coordinating center in dry ice. After biological sample collection shipment will be scheduled with', 'each center. Samples will be shipped to Medical Oncology. Translational Oncology Lab, S. Croce e', 'Carle Hospital, Cuneo', '11.3.2 Analysis', 'The following cell population will be studied by flow cytometry:', 'CD3+ CD4+ CD25+ Foxp3+T-lymphocytes', 'CD3+ CD8+ T-lymphocytes', 'NK cells: CD3-CD56+', 'MDSC: CD33+ CD11b+ CD14- HLA-DR(low)', 'myeloid DC HLA-DR+lindim/negative/CD11c+ and plasmacytoid DC HLA-', 'DR+lindim/negative/CD123+', 'VEGF, TGF-beta and the other cytokines and interleukins will be studied using commercial', 'available kit:', '- Thl: IL-2, IL-12, IL-15, IL-21, IFN-y and TNF-a', '- Th2: IL-4 (B cell stimulating factor BSF-1), IL-5, IL-6, IL-10, IL-13 HSP70, HSP90,', 'EpCAM e and HMBG1 will be measured with ELISA Kit commercial available.', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '46']['11.4 Statistical Analysis of translational data', 'We shall evaluate circulating factors that are significantly changing during treatment period, by', \"means of the Wilcoxon's test, and in particular variation between:\", 'baseline to the day after radiotherapy', 'baseline to the start of cycle 2', 'baseline to disease progression.', 'Considering the large number of comparisons planned, we will adjust for multiple testing using the', '\"false discovery rate method\" which is the adequate standard procedure of adjustment for multiple', 'testing.', 'The correlation between the level pattern of circulating immunological factors at baseline and', 'during treatment on and clinical objective response (responders vs non-responders) will be', 'essentially descriptive and do not applied formal statistical texts.', 'The interpretation of the data collected will be conducted in collaboration with the Institute of', 'Candiolo tumors by Prof. M. Aglietta and Prof. D. Sangiolo. The statistical analysis will be', 'conducted by University of Turin (Prof. M. Di Maio).', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '47']\n\n###\n\n", "completion": "END"}